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THE ROLE OF IMMUNE RESPONSE IN TRAUMATIC INJURY  
GERMÁN MARTINEZ  
ABSTRACT 
 The host immune response to traumatic injury is complex with potentially serious 
consequences in certain situations. Research has shown that the immune system response 
after injury is dynamic with both arms of the immune system associated in the response. 
Building on existing work on trauma research, the exact mechanisms for how the immune 
system wreaks havoc in some trauma patients in the body’s attempt to restore 
homeostasis is not fully understood. An immunological cascade initiated after injury by 
certain innate immune cells has been indicated as the main catalyst for serious 
complications after trauma in SIRS (Systemic Inflammatory Response Syndrome). SIRS, 
a serious medical complication with inflammation throughout the body, is often 
associated with other conditions such as multiorgan failure leading to death. Early 
treatment and medical intervention are imperative in increasing the survival chances in 
those with severe complications. Despite the advances in medicine in the last few 
decades, therapeutic solutions to address these issues are still ongoing given the complex 
workings of the host immune system. This review aims to examine the immune response 
in various types of injuries, post injury impacts, current treatments, and ongoing research 
aimed at developing better therapeutic strategies.    
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In a recent study from the World Health Organization, trauma is responsible for 
10% deaths and 16% disabilities globally, more than malaria, tuberculosis, and 
HIV/AIDS combined [1]. The peak age group of patients with traumatic injuries occurs 
in the second decade of life. However, older trauma victims have become more frequent 
as populations age. Without any medical care or intervention, most people with severe 
injuries  such as from traffic accidents will bleed to death. With advances in hemorrhage 
management in trauma patients, more patients today are now able to survive. Despite 
these advances, serious complications arise in many trauma patients the two most serious 
being sepsis and multiorgan failure because of systemic response to severe injury. The 
development of multiorgan failure (MOF) after severe trauma is one of the leading causes 
of late mortality in trauma patients. The associated mortality varies from 27% to 100% 
and increases with the number of impacted organs [2]. Sepsis is a massive and expensive 
medical issue throughout the world. In North America, it is estimated that there are more 
than 600,000 cases of sepsis each year, with a mortality rate between 30-50% [3].   
 Severe injury is associated with Systemic Inflammatory Response Syndrome 
(SIRS). This response plays a role both in the development of MOF and sepsis.  SIRS is 
initiated within thirty minutes of a critical injury and is an inflammatory response to 
blood loss and tissue damage rather than infection. SIRS results from release of 
endogenous factors known as DAMPS or ‘alarmins’ after tissue injury that activate innate 
immunity [4]. They are secreted by neutrophils or released from necrotic cells [5][6]. 
Mitochondrial DNA and peptides released during necrosis trigger a vigorous foreign 
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body reaction. DAMPS activate immune cells such as neutrophils and monocytes through 
DAMPS receptors [5].  DAMPS are activators of the complement, leading to quick 
generation of C3a and C5a [7]. Activation of complement and inflammatory cells causes 
the production and release of inflammatory mediators such as interleukins.  
The immune system has a series of feedback loops to restore homeostasis. SIRS is 
associated with an anti-inflammatory response defined by elevated levels of anti-
inflammatory cytokines (ex. IL-10) and cytokine antagonists (ex. IL-1-Ra) [8]. 
Depending on the balance of pro- and anti-inflammatory mediators, the response could 
return to baseline or progress to post-intensive care syndrome (PICS) with an elevated 
risk of multiorgan failure and sepsis [9]. The pathogenesis of PICS involves chronic low-
grade inflammation, suppressed host protective immunity, and loss of tissue [10]. 
Therapies to remediate PICS and problems associated in SIRS are still ongoing. Although 
the host immune response to trauma has adverse effects that can result in severe 
complications such as SIRS or MOF, the immune response to injury is part of the body’s 
attempt to restore homeostasis in the process, with early interventions and therapies most 
immunological responses can be controlled leading to recovery.  
The initial concepts of immune dysregulation and dysfunction came from a 
consensus meeting in 1991 describing the whole-body response to an infectious or 
injurious stimulus as systemic inflammatory response syndrome (SIRS) [11]. These 
concepts evolved to include the response of counter-regulatory mechanisms designed to 
dampen the initial pro-inflammatory signal, termed the compensatory anti-inflammatory 
response syndrome (CARS) [12]. Recent understanding of the integrated pro-and anti-
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inflammatory responses to injury has led to a form of immune dysregulation, termed 
persistent inflammation-immunosuppression and catabolism syndrome (PICS) (figure 1) 
[13].  
 
Figure 1. Temporal association of immune dysfunction syndromes. (Figure taken from [14]) 
After initial combat-related injury, there is the development of a hyper-inflammatory response, 
known as the systemic inflammatory response syndrome (SIRS), and an immune suppressing 
response, termed the compensatory anti-inflammatory response (CARS). These two responses 
occur within minutes to days, occurring nearly simultaneously, and is during these inflammatory 
responses that death from early multi-organ dysfunction (MODS) might occur. As both the pro-
inflammatory and anti-inflammatory responses resolve, there is a period of resolution, usually 
within days to weeks, that allows for homeostasis return and survival after injury. Nevertheless, 
in a certain percentage of injured patients, the pro-inflammatory responses never resolve, causing 
a period of chronic critical illness termed persistent inflammatory-immunosuppressive and 
catabolic syndrome (PICS). This happens in patients who have been critically ill for longer than 
14 days with significant lymphopenia and chronic inflammation. PICS can persist for months and 
lead to the risk for developing later MODS and secondary infection with subsequent morbidity 
and late mortality.    
 
This review will examine the immune response in various types of injuries, post 
injury impacts and current treatments.  Present research aimed at developing better 
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therapeutic strategies will also be presented as well as future opportunities and challenges 
in trauma research. 
CENTRAL NERVOUS SYSTEM INJURY  
 
A. Traumatic Brain Injury  
Traumatic brain injury (TBI) is one of the leading causes of mortality and disability 
globally, with high incidence in both civilian and military populations. Nearly 1.7 million 
people in the United States are impacted with TBI annually, which contributes to 30% of 
all injury-related fatalities and an annual cost of roughly $60 billion [15]. TBI is 
challenging to treat because they are heterogenous in nature and include complex 
pathogenesis pathways. Clinical outcomes following TBI are determined by the nature 
and severity of primary injury. The mechanical effects of trauma can also cause injurious 
biochemical cascades known as “secondary injury” [15].  
Primary injury occurs at the time of head impact and results in direct damage to 
neural tissue. Focal intracranial hemorrhage, brain contusion, and direct axonal damage 
are all prime examples of primary lesions [15] [16]. On the other hand, secondary injury 
occurs minutes to months following mechanical insult, progressively aiding to 
neurological impairment. At the cellular level, secondary injury is mediated by several 
pathways such as excitotoxicity caused by excess glutamate (neurotransmitter) and 




Over the years, there has been an increasing understanding of role that the immune 
system plays in TBI pathogenesis. An immune response develops within minutes of TBI 
and includes local signaling in neurons, glia, and recruited peripheral immune cells that 
causes an inflammatory cascade. A typical inflammatory cascade with key immune cells 
is shown in figure 2.  
 
Figure 2. Temporal Progression of Immune Response to TBI (figure taken from [15] ) 
Within minutes of brain injury, the release of alarmins from damaged meninges, glial limitans, 
and parenchyma (ex. ATP) occurs in phase 1. These signals bind to PAMP and DAMPS sensors 
like TLRs and induce immediate activation of resident myeloid cells (ex: microglia) and 
inflammasome assembly (NALP1) that promotes the generation of IL-1β and IL-18. NF-kβ 
translocates to the nuclei of these cells and induces a response involving cellular proliferation and 
the release of inflammatory amplifiers such as chemokines and cytokines. This response includes 
complement activation and neutrophil recruitment to the meninges and perivascular spaces. 
Secondary damage to CNS tissue occurs in phase 1 and phase 2. T cells and monocytes are 
recruited to the damage site in phase 2, where monocytes covert into macrophages and T cells can 
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produce neuroprotective cytokines in response to alarmins. Macrophages participate in cleanup of 
debris and damaged cells. Depending on their function activation state, they can either promote 
further damage or initiate the process of inflammatory resolution and tissue repair. Inflammation 
can continue for a prolong duration into phase 3. Self-antigens released from damaged neural 
cells can be presented by local antigen-presenting cells (APCs) to T cells. The ideal outcome of 
phase 3 is resolution of the inflammatory response, release of trophic factors, and isolation of 
damaged areas via astrocytes. Nevertheless, this does not always occur following TBI and 
chronic inflammation can persist.  
 
The expression of inflammatory factors happens early after TBI, which helps orchestrate 
the activation of resident and peripherally immune cells. Immune signaling in the 
damaged or infected CNS is mediated partly by DAMPs or PAMPs. These molecules 
interact with receptors such as TLRs (Toll like Receptors), NLRs (Nucleotide binding 
and oligomerization domain like receptors), and scavenger receptors that function as 
“danger” sensors and initiate the inflammatory cascade as seen in figure 2.  After 
recognition of endogenous proteins released by damaged cells (ex. alarmins and other 
DAMPs), a cellular response is triggered from several kinases which results in NF-kβ 
activation [19]. NF-kβ expression is elevated after TBI and associated with elevated 
levels of inflammatory cytokines such as IL-6 and tumor necrosis factor [20]. HMGB1 is 
a dual function protein that serves as a cytokine and directly binds chromatin triggering a 
danger signal in response to tissue injury [21]. Immune cells release HGMB1, which can 
bind to TLR4 and initiate an inflammatory response.  
 Heat shock proteins (HSPs) are another important protein family involved in 
tissue damage response in TBI. HSPs are protein chaperones that are induced upon 
cellular stress, during states of injury and wound healing. HSPs are known to participate 
in early TLR/NLR signaling and can serve as TLR ligands. HSPs have both inflammatory 
and anti-inflammatory effects. For instance, HSPs can stimulate immune response by 
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playing a role in antigen presentation [22]. Following brain injury, overexpression of 
HSP70 in mice reduced brain lesion size and expression of metalloproteinases, whereas 
HSP70 deletion in mice enhanced brain damage following TBI [23] [24].  
 NLRs are cytosolic receptors for PAMPs and DAMPs and following recognition 
of DAMPs, a subset of NLR (ex. NLRP1) and non-NLR proteins assemble into a 
macromolecular complex known as the inflammasome [25]. This complex promotes 
cleavage of caspase-1 into its active form through various interactions. Active caspase-1 
induces the generation of mature IL-1β and IL-18, which play an important role in sterile 
immune responses following brain injury [26]. Inflammasomes assembled in multiple 
CNS cell populations including astrocytes and microglia and upon activation are involved 
in the generation of pro-inflammatory cytokines. In one study, inflammasome proteins 
such as NLRP1 and caspase-1 have been detected in cerebrospinal fluid (CSF) of patients 
with moderate to severe TBI and high levels of these proteins correlated with a more 
unfavorable neurologic outcome [27].  
 Microglia are CNS residents and among the first responders to brain injury. They 
are distinct from bone-marrow derived monocytes/macrophages. After brain injury, 
microglia usually respond within minutes by projecting processes at the damage site. 
Imaging studies in humans show that microglia activation can be sustained years after 
TBI [28]. The microglial response to TBI has many phases that include morphological 
transformation, electrophysiological changes, proliferation, and phagocytosis [29]. 
Microglia can be neuroprotective post brain injury. They participate in the cleanup of 
dead cells and help maintain CNS barrier integrity structures including glial limitans [30].  
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 Astrocytes are involved in homeostatic functions of the CNS and blood flow 
control [31]. Astrocytes create a function barrier via the interaction of their foot processes 
with the parenchymal basement membrane called glia limitans. This barrier separates the 
CNS from blood vessels, perivascular spaces, and the meninges. Furthermore, the barrier 
serves as a checkpoint that controls influx of blood-borne immune cells [32].  Reactive 
astrogliosis is important in scar formation after injury and it helps contain the damage and 
inflammatory response to the injured area, thus limiting the spread of those changes to 
unaffected areas. Furthermore, astrocytes can play a role in repairing the blood brain 
barrier (BBB) and maintaining homeostasis by providing metabolic support for neurons 
and synapses [33].  
 Matrix Metalloproteinases (MMPs) are a family of calcium-dependent zinc-
containing endopeptidases that have varied physiological and pathological functions 
including regulation of cytokines/chemokines and extracellular matrix degradation [34]. 
These enzymes are created as zymogens that must be converted into an active form via a 
pro-peptide removal domain. Once active, MMPs serve on different substrates to mediate 
their effects. Expression of the neutrophil collagenase, MMP-8, was associated with 
significant increasing intracranial pressure and higher in patients that died after TBI [35].  
 The adaptive immunity’s role following TBI remains not entirely understood. 
Studies have demonstrated that autoreactive T cells specific to CNS antigens (ex: myelin 
basic protein) can be isolated from blood of healthy people and those with TBI [36] [37]. 
TBI can result in a cell-mediated immune response with T cells being recruited to CNS 
independent of their specificity [38][39]. In one study, autoreactive CD4+ T cells specific 
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to CNS antigens were shown to protect injured axons after damage [40]. This might be 
from the ability of CD4+ T cells to release IL-4 in areas of CNS injury [41]. Some 
humoral responses have been observed following head injury [42]. Additional studies are 
needed to assess the role of adaptive immunity in other models of TBI and later 
timeframes post injury.   
 Over the last few years, there is growing evidence to support the conclusion that 
TBI is a major risk factor for developing many neurological disorders, such as 
Alzheimer’s disease and chronic traumatic encephalopathy (CTE) [43]. Repeated mild 
TBI can result in sustained cognitive and psychiatric changes including 
neurodegeneration, however the exact mechanisms are not fully understood. Chronic 
inflammation induced from brain injury is suggested as a major factor in the 
pathophysiology of neurodegenerative conditions [44]. Numerous studies linked TBI to 
Alzheimer’s disease and suggest a dose-dependent relationship between head injury and 
dementia predisposition. The pathological mechanisms for protein aggregates depositions 
include white matter disruption and release/deposition of amyloid beta (Aβ) and tau [43].  
The buildup of these neurotoxic forms is believed to create the neuroinflammatory 
responses that drives Alzheimer’s disease after brain injury [45].   
B. Spinal Cord Injury  
Spinal cord injury (SCI) is a crippling neurological condition with severe 
consequences on affected individuals and the health care system. According to the 
National Injury Statistical Center, there are over 12,500 new cases of SCI annually in 
North America. More than 90% of these injuries are traumatic and mainly related to 
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traffic accidents or falls [46]. Demographically, men are mostly affected during their 
early and late adulthood, while women are at higher risk in their adolescence and 7th 
decade of their lives [47]. The age distribution is bimodal, with the first peak associated 
with young adults and second peak with adults over the age of 60. Adults over 60 years 
of age who suffer from SCI have worse outcome than younger patients in part from falls 
and age-related bone changes [46].  
SCI typically results from a sudden, traumatic impact on the spine that fractures 
or dislocates the vertebrae. The mechanical forces delivered to the spinal cord at the time 
of injury are considered as primary injury where displaced  bone fragments, disc 
materials, and/or ligaments tear into the spinal tissue[47]. Some of the characteristic 
mechanisms of primary injury include impact plus persistent compression and impact 
alone with transient compression [48][49]. The most common form of primary injury is 
impact plus persistent compression, which occurs through burst fractures with bone 
fragments compressing the spinal cord. Impact alone with transient compression is 
observed less and most commonly in hyperextension injuries [48]. There are clearly 
distinct differences between the outcomes of SCI in military and civilian cases. Blast 
injury is the most common cause of SCI in the battlefield that involves multiple segments 
of the spinal cord [50]. In addition, blast SCI results in elevated severity scores and 
associated with longer hospitalization [51].   
Secondary injury occurs within minutes following primary injury and continues 
for weeks or even months causing progressive spinal cord tissue damage around the 
lesion site [48]. This type of injury can be divided into acute, sub-acute, and chronic 
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phases. The acute phase starts immediately following SCI and includes vascular damage, 
ionic imbalance, and free radical formation [46]. As the injury progresses, the sub-acute 
phase begins involving apoptosis, demyelination of surviving axons, and evolution of 
glial scar around injury site. Further changes occur in the chronic phase including 
maturation of the glial scar [52][53].  
Neuroinflammation is key factor of secondary injury mechanism with local and 
systemic outcomes. Initially, inflammation was thought to be detrimental for SCI 
outcome, however now it is well recognized that inflammation can be both beneficial and 
detrimental following injury, depending on time point and activation of immune cells 
[54][55]. There are multiple cells involved in the inflammatory response after injury 
including neutrophils, resident microglia, astrocytes, dendritic cells (DCs), B and T-
lymphocytes as shown in figure 3. The first phase of inflammation (0-2 days post injury) 
involves the recruitment of microglia, astrocytes, and neutrophils to the injury site [56]. 
The second phase of inflammation (3 days post injury) is characterized by the recruitment 
of macrophages, B- and T-lymphocytes to the injury site [57] [58]. T lymphocytes 
become activated in response to antigen presentation by macrophages and other antigen 
presenting cells (APCs). CD4+ helper T cells produce cytokines that stimulate B cell 
antibody production and activate phagocytes (Figure 3). In spinal cord injury, B cells 
make autoantibodies against injured spinal cord tissue, which worsen neuroinflammation 
and causes tissue destruction [59]. Microglia macrophages, T cells, and B cells can adopt 
either a pro-inflammatory or an anti-inflammatory regenerative phenotype in injured 




Figure 3. Immune response in spinal cord injury. (Figure taken from [46])  Under normal 
circumstances, there is an equal balance between pro-inflammatory effects of CD4+ effector T 
cells (Teff) and anti-inflammatory effects of regulatory T and B cells (Treg and B reg). Treg and Breg 
suppress the activation of antigen specific CD4+ Teff cells through production of IL-10 and TGF-β. 
Injury disrupts this balance and promotes a pro-inflammatory environment. Activated 
microglia/macrophages release pro-inflammatory cytokines and chemokines and present antigens 
to CD4+ T cells causing activation of antigen specific effector T cells. Teff cells stimulate antigen 
specific B cells to undergo clonal expansion and produce autoantibodies, against spinal cord 
tissue antigens. These autoantibodies cause neurodegeneration through FCR mediated 
phagocytosis or complement mediated cytotoxicity. M1 macrophages/microglia release pro-
inflammatory cytokines and reactive oxygen species (ROS) that are damaging to neurons and 
oligodendrocytes. Breg cells possess the ability to promote Treg development and restrict Teff cell 
differentiation. Breg cells could induce apoptosis in Teff cells through Fas mediate mechanisms.   
 
Although astrocytes are not considered immune cells, they play vital roles in the 
neuroinflammatory processes during CNS injury and disease as well as in maintaining 
CNS homeostasis [61]. Astrocytes contribute to both innate and adaptive immune 
responses following SCI by differential activation of their intracellular signaling 
pathways in response to environmental signals to produce cytokines and chemokines 
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[62]. They mediate chemokine production, such as MCP-1 and CCL-2 , enhancing the 
recruitment of neutrophil and pro-inflammatory macrophages to the injury site through 
IL-1R-Myd88 pathway [63].   
 Neutrophils infiltrate the spinal cord from the bloodstream within the first several 
hours after injury. Their population increases and peaks within 24 hours post injury. The 
presence of these cells is usually limited to the SCI acute phase and are rarely found in 
the sub-acute phase of the injured spinal cord [64]. Evidence demonstrates neutrophils 
contribute to phagocytosis and clearance of tissue debris. They release pro-inflammatory 
cytokines, proteases, and free radicals to degrade ECM [65]. In one study, it was shown 
that stimulated neutrophils release IL-1 receptor antagonists that can exert 
neuroprotective effects post SCI [66]. Furthermore, ablation of neutrophils results in an 
altered cytokine and chemokine expression and downregulation of growth factors such as 
FGFs in the injured spinal cord that disrupt the normal healing process [67].  
 Upon neutrophil invasion, microglia/macrophages populate the injured spinal 
cord within 3 days of SCI. Macrophage populations are derived from blood-borne 
monocytes or originate from CNS resident macrophages that reside within meninges and 
subarachnoid space [68]. While microglia and macrophages share many functions and 
immunological markers, they have different origins. Microglia are local immune cells of 
the CNS that originate from yolk sac during embryonic development while macrophages 
derived from blood monocytes, which originate from myeloid progeny [69].  Upon 
injury, monocytes cross the BBB to infiltrate the spinal cord tissue and convert to 
macrophages. Macrophages populate mainly the site of primary injury, while microglia 
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are usually in the perilesional area [70]. Macrophages/microglia play a beneficial role in 
CNS regeneration. Both promote the repair process by expression of growth factors such 
as a nerve growth factor (NGF) and neurotrophin-3 (NT-3) [71]. They are important for 
wound healing process post SCI due to their ability for phagocytosis, scavenging 
damaged cells, and myelin debris following injury [72].   
 T and B lymphocytes play critical roles in the adaptive immune response after 
SCI. These lymphocytes infiltrate the injured spinal cord during the first week of injury 
and remain chronically elevated in mouse and rat SCI [73]. The adaptive immune 
response requires a complex signaling cascade in T cells prompted by antigen presenting 
cells [74]. Spinal cord injury elicits a CNS-specific autoimmune response in T and B 
cells, which remains active chronically. T cells can indirectly impact neural cell function 
and survival through pro-inflammatory cytokine and chemokine production (ex. TNF-α, 
IL-12, and CCL5) [75]. In one study, genetic elimination of T cells (in athymic nude rats) 
leads to improved tissue preservation and SCI functional recovery [76]. Evidence shows 
that SCI can suppress B cell activation and antibody production [77]; however, this seems 
to be influenced by level of injury [78].  
 Spinal cord injury is associated with potentially dangerous complications as 
shown in table 1, therefore it is imperative that we better understand the cellular and 




Table 1. Organ System Complications following spinal cord injury. [79]   
 
More than half of all SCI patients will develop complications during their hospital stay, 
with higher rates corresponding to increase injury severity, the presence of traumatic 
brain injury and cerebrovascular damage occurring with spine injury [79]. SCI may result 
in multi-organ system complications related to infectious morbidity (table 1).  
Respiratory compromise and shock are primary concern when managing SCI patient’s 
treatment.  
C. Hypoxia Ischemia Injury  
Perinatal hypoxia-ischemia (HI) induced brain injury is one of the most common 
form of neonatal brain injury that occurs in nearly 3 per 1000 term newborns and about 7 
per 1000 preterm newborns. HI can be caused from several reasons including birth 
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asphyxia and traumatic brain injuries (ex: motor vehicle crashes).  Approximately 40% of 
newborns with HI brain injury do not survive in the neonatal period and about 30% 
develop long-term neurological disorders (ex: seizures). In developing countries, the 
incidence jumps up to nearly 26 per 1000 term newborns, with less survivors [80]. 
Perinatal HI brain injury has been a leading global public health problem and a 
substantial burden to society.  
Inflammation has been considered an important contributor in the 
pathophysiology of HI injury. HI triggers immediate and robust activation of CNS 
resident cells and subsequent infiltration of circulating peripheral leukocytes.  The initial 
inflammatory response to this injury causes secondary neuronal injury that can last for a 
few days, accompanied by anti-inflammatory response towards inflammation resolution. 
Countless studies have highlighted the critical functions of resident immune cells and 
peripheral innate immunes cells in promoting brain injury and ensuing tissue 
repair/remodeling at various time points of the HI cascade [81]. The exact mechanisms of 
resident and peripheral innate immune cell activation and interaction with brain cells in 
immature brain following this type of injury remains unclear.    
The pathophysiology of neonatal hypoxic-ischemic encephalopathy (HIE) results 
from blood flow reduction and oxygen delivery to the brain. HIE is caused primarily 
from perinatal asphyxia. Perinatal asphyxia is mainly caused by systemic hypoxemia 
and/or reduced cerebral blood flow.  Severe acute HI leads to rapid neuronal death via 
necrosis, while energy failure (big drop in ATP production) following less prolonged HI 
causes slower neuronal death through apoptosis [82]. Hypoxia-ischemia induced neuronal 
17 
 
death is described in two phases. The severe form causes primary energy failure leading 
to primary neuronal death, related to a significant reduction of ATP and increased lactate 
production. Low ATP levels causes failure of the energy-dependent cell membrane ion 
channels responsible for neuronal cell integrity, which in part causes intracellular influx 
of ions and membrane depolarization [76]. Increased lactate levels increase reactive 
oxygen species levels. All these changes lead to rapid cell swelling and necrosis. 
Secondary energy failure occurs six hours after primary injury. This phase results in 
delayed neuronal death with apoptosis, which consists of several mechanisms, such as 
oxidative stress and inflammation [83]. The delayed neuronal death contributes a major 




Figure 4. The pathogenesis of hypoxic-ischemic encephalopathy. (Figure taken from [80] ).  
Neonatal hypoxia-ischemia results in deprivation of energy substrates, oxygen, and glucose to 
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brain tissue, and transforms the cells to anaerobic metabolism. The ATP reductions aids in the 
failure of the energy-dependent cell membrane ion-channels, which causes an acute intracellular 
influx of calcium and sodium and cell membrane depolarization, as well as extracellular 
glutamate accumulation. This cascade leads to cell swelling and necrotic cell death. If the initial 
insult is prolonged or severe, it may result in a secondary delayed energy failure within hours 
causing cell death mostly via apoptosis. During this phase, excitotoxicity, inflammation, and 
uptake of intracellular calcium as well as reactive oxygen species are observed. Upon the 
secondary phase of injury, another chronic phase of injury occurs within days and can continue 
for months. This phase includes astrogliosis, chronic inflammation, and tissue repair and 
remodeling, which contributes to loss of brain cells and cerebral atrophy.    
 
Hypoxia-ischemia results in notable microglial activation in the neonatal brain. A clinical 
study has shown substantial microglial infiltration is shown in the polymorphous layer of 
dentate gyrus of infants that died from HIE, whereas those dying of trauma or sepsis have 
drastically fewer microglia [84].In a rat model of HI brain injury, microglial activation 
was detected as early as two hours after insult [85]. Microglial contribution in secondary 
energy failure after HI is characterized by M1 macrophage activation. M1 macrophages 
exert toxic effects on neurons and glia in the injury site through release of pro-
inflammatory cytokines (ex. IL-6 and IL-18), complement factors, and proteases [86]. 
Furthermore, excessive production of ROS and NO activated by microglia can induce 
oxidative injury in the developing brain [87]. Microglia have been implicated as a 
crucially player in the resolution of inflammation and reparative processes after acute HI 
injury. Phagocytosis of debris by microglia is critical for recovery of injured brain during 
the delayed phase after neonatal stroke. Selective ablation of microglia resulted to higher 
levels of pro-inflammatory cytokines and chemokines and exacerbation of brain injury in 
neonatal and adult stroke models [88]. 
19 
 
 Astrocytes are the most common cell type in the CNS and outnumber neurons by 
five-fold. Astrocytes exert essential functions in the maintenance of BBB integrity and 
nearby neurons. These cells are responsible for glutamate uptake, indicating they may 
prevent excitotoxic neuronal damage [89]. Furthermore, they aid in homeostasis of 
extracellular ions (ex. potassium) and are involved in the antioxidant defense of the CNS 
[90]. Pro-inflammatory cytokines and reactive oxygen species released by damaged 
neurons in HI conditions can trigger astrogliosis. Astrogliosis is frequent within white 
matter in up to 40% of infants with HI brain injury [91]. Following HI injury impairment 
of glutamate transporters on astrocytes directly causes the buildup of extracellular 
glutamate, which contributes to deleterious events in the developing brain [92]. 
Moreover, numerous evidences show that reactive astrocytes stimulate the production of 
anti-inflammatory cytokines, including IL-9, IL-10, and IL-11 and facilitate tissue repair 
via TLR-3 activation [93]. This suggests that astrocytes may play an important role in the 
inflammation resolution and tissue repair in neonatal brain injury.   
 Monocytes are important blood-borne cells that are involved in phagocytosis, 
bactericidal activities, and antigen presentation to T cells. Blood monocytes are 
precursors of macrophages or dendritic cells in tissues. During CNS inflammation, 
circulating monocytes travel to the brain and give rise to CNS macrophages [94]. 
Myeloid cell infiltration peaks at 24 hours following neonatal HI injury, and the 
infiltrating cells consist mainly of monocytes [90]. In one study, CCR2 deletion in bone 
marrow-derived monocytes/macrophages resulted in delayed exacerbation , suggesting 
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that CCR2+ bone marrow-derived monocytes/macrophages play a vital role in maintain 
integrity of the neurovascular unit after ischemia [95].  
 Dendritic cells are specialized APCs that serve as a bridge between innate and 
adaptive immune responses. DCs are involved in antigen capture, processing, and 
presentation to T lymphocytes to cause either tolerance or adaptive immunity. Dendritic 
cells not only produce pro-inflammatory cytokines in the ischemic brain but might also 
initiate a T cell response in secondary inflammation to brain ischemia [96]. The presence 
of APCs in neonatal HI brain injury is still not fully understood. However, it appears that 
neonatal HI injury leads to activation of DCs with upregulation of costimulatory 
molecules, CD86 and MHC-II, in the injured brain and the periphery [97].  
The adaptive immune response modulates the balance between inflammatory and 
anti-inflammatory pathways, as well as the development of immune cell memory through 
the recognition of specific antigens on APCs, which induces clonal expansion of effector 
T cells. In neonatal HI models, the infiltration of CD4+ and CD8+ T cells to the immature 
brain usually 24 hours and peaks within 1-2 weeks after HI insult [97]. Current studies 
indicate that T cells play a neurotoxic role in short term acute ischemic brain injury as 
shown by the fact that blocking T cell migration and depletion reduce damage after 
ischemia in adult animals [98]. Growing evidence suggests that T cells play a more vital 
role in the chronic inflammation in neonatal models. In a neonatal HI injury, CD4+ T 
lymphocytes were detected in the damaged brain hemisphere within the first peak one 




 B lymphocytes, unlike T cells, express B cell receptors that mediate the antibody 
production through binding to one specific antigen. B cells also present antigens, produce 
cytokines, and regulate T cell activities in many inflammatory diseases. Neonatal B cells 
are naïve, lack antigenic exposure, have a partially developed surface immunoglobulin 
repertoire, and deficient in neonatal antibody production. This suggests that immature B 
cells and are more like T cells in neonates [97].  A decreased in B lymphocyte activation 
and frequency is associated with larger damage [99]. B cells play a role in resolution of 
inflammation and tissue repair in neonatal HI brain injury. In addition, absence of B cells 
leads to larger infarct volumes in adult stroke and elevates the number of microglia, 
monocytes, and activated T cells in the ischemic brain [100].   
 One study has provided evidence that activation of APCs and T cells is present in 
circulation and peripheral organs three months after neonatal HI indicating long-lasting 
inflammation persists in newborns with HIE [97]. A harmful role of autoimmune 
response in ischemic brain injury development has emerged from stroke studies. 
Autoreactive T cells and higher levels of antibodies against brain antigens have been 
observed in adult stroke patients. Blocking autoreactive T cell response with artificial T-
cell ligands reduces lesion volumes 96 hours post stroke [101][102]. This suggests that 
neonatal hypoxia-ischemia induced autoimmunity may play a factor in 
neurodevelopmental impairments. In addition, the development of peripheral T cells 
specific to brain antigens during neonatal period may increase the risk of brain injury 
later in life, when damage to the BBB may occur allowing migration of that same 




Skeletal muscle injuries occur frequently, partly because muscles comprise a 
major proportion of total body mass and are located superficially where they are prone to 
trauma. Muscle injuries increased globally over the last 20 years, in part because of 
increased blast injuries during armed conflicts and trauma in road traffic accidents, 
accounting for millions of injuries every year. Furthermore, recovery from medical 
conditions involving muscle mass loss can be impaired by the limited rates of muscle 
regeneration and growth, resulting in prolonged functional impairment even after patients 
resume daily activities [103].  
Muscle regeneration begins with the activation of myogenic precursor cells 
(MPCs) known as satellite cells that reside on muscle fibers surface [103]. Following 
muscle damage, satellite cells escape quiescence and start proliferating and 
differentiating. Postmitotic MPCs derived from activated satellite cells form 
multinucleated myotubes which can further terminally differentiate and growth. Each 
stage is associated with changes in expression of myogenic transcription factors that are 
encoded by master regulatory genes [104].  Quiescent satellite cells expressed a paired 
box transcription factor (PAX7) but do not express the basic helix-loop-helix (bHLH) 
transcription factor myoblast determination protein 1 (PAX7+MYOD-). Activated 
satellite cells are daughter MPCs that undergo differentiation express the bHLH protein 
myogenin [103]. Satellite cells and their progeny are critical for muscle regeneration. 
Depletion of satellite cells abolishes the regeneration of injured muscles [105].  
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Muscle damage induced by acute trauma, burns, freezing, toxins, or some 
diseases initiates an inflammatory response in which the number of intramuscular 
leukocytes increases more than 100-fold. Within several hours, neutrophils invade 
damaged muscle and peak approximately about 12-24 hours post injury, then receding 
back to normal levels. Resident macrophages that lack expression of CXC-chemokine 
receptor 1 (CXCR1) promote the neutrophil influx by increasing the neutrophil 
chemoattractants CXC-chemokine ligand (CXCL1) and CC-chemokine ligand 2 (CCL2) 
[106]. Several studies have established the importance of CCL2-mediated signaling in 
driving muscle inflammation and muscle regeneration following injury.  Early arrival of 
neutrophils in injured muscle enables them to condition the inflammatory environment to 
influence the activation state of other immune cell populations. Circulating monocytes 
and macrophages enter the injured muscle enriched with pro-inflammatory cytokines, 
including interferon-γ (IFNγ) and tumor necrosis factor (TNF) [107]. These cytokines can 
activate macrophages to a pro-inflammatory phenotype, and these macrophages are 
called M1 macrophages to reflect their activation by pro-inflammatory T helper 1 (TH1) 
type cytokines [108]. This differentiates them from M2 macrophages, which are activated 
by TH2 type-cytokines and are associated with resolution of inflammation and tissue 
repair.  
Within the post-injury debris and inflammatory lesions, when neutrophils and 
macrophages, mainly of M1 phenotype, are at their peak, the first stage of tissue 
regeneration is dependent on IFNγ-mediated pathways [109]. IFNγ regulates gene 
expression in muscle cells through MHC class II transactivator (CITTA) [110]. IFNγ-
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mediated induction of CITTA expression is vital for inhibiting MPC differentiation as 
shown by the fact that IFNγ-mediated suppression of myogenin, an essential transcription 
factor for muscle terminal differentiation, is impaired when CITTA expression is 
knocked down [110]. Hence, IFNγ-mediated mechanisms are crucial to coordinate for 
immune response to muscle injury during early stage muscle regeneration.   
Neutrophils and macrophages are a major source of TNF-α following an acute 
injury [111]. Although TNF-induced activation of nuclear factor-kB (NF-kB) in myeloid 
cells can influence their activation and interactions with injured muscle, TNF can directly 
act on muscle cells to impact muscle regeneration. This cytokine has epigenetic effects on 
muscle regeneration by targeting NOTCH1, a transmembrane receptor expressed in 
muscle cells crucial for muscle development. NOTCH1 stimulates myogenesis  mainly 
via MYOD inhibition, myogenin, and myocyte specific enhancer factor 2C (MEF2C) 
expression, leading to proliferation and reduced differentiation of MPCs [112] [113]. 
Taken together, IFNγ and TNF can activate macrophages to a M1-biased phenotype in 
injured muscle and regulate proliferation and differentiation of MPCs.  
The notion that lymphocytes do not play a relevant role in healthy regenerating 
muscle, due to the inability of skeletal muscle to activate a T cell response is widely 
accepted. Neither MHC class I nor class I molecules have been detected in muscle fibers 
from healthy muscle tissues [114]. On the contrary, MHC class I and or II was observed 
in muscle tissue of patients with idiopathic inflammatory myopathies (IIM), where an 
autoimmune pathogenesis is believed to be the culprit [115]. T cells are found in 
degenerating muscle after injury, but recruitment is much more robust and persistent in 
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chronic diseases such as muscular dystrophies, where B cells can also be found [116].  
Mechanisms underlying T cells recruitment, expansion, and persistence in acutely injured 
muscle are still under investigation. In one study, acute myofiber damage transiently 
activated muscle-antigen specific CD8+ T cells in the draining lymph nodes, supporting 
the notion of a transient autoreactive immune response upon muscle injury. These 
activated T cells invade injured muscle and their negative impact on muscle repair is 
controlled by immunosuppressive cues [117].   
When immune cell modulation of muscle regeneration is impaired due to a lack of 
the immune system adaptation to chronic injuries, may lead to muscle fibrosis and 
impaired regeneration. These regenerative defects are most accurately shown in the mdx 
mouse model of DMD (Duchene Muscular Dystrophy). DMD and mdx dystrophy 
involves a mechanically weakened cell membrane, which can lead to chronic muscle 
damage and inflammation [118]. While many pathological features arise from chronic 
muscle injury, disruptions of the normal immune response to muscle damage worsens the 
pathology [119]. Chronic injury causes the alteration of  mdx macrophages to phenotypes 
with an abnormal regulation of connective tissue production. In early stages of chronic 
damage, these macrophages express both M1 and M2 phenotypic markers and, unlike 
M2-macrophages from injured wild type muscle, these transitional macrophages are 
unable to induce FAP (fibro-adipogenic progenitors) leading to cell apoptosis and 
increased connective tissue deposition [120] (Figure 5). In later stages of mdx dystrophy, 
M2-biased macrophages shift to a highly fibrogenic state in which there is enhanced 




Figure 5. Dysregulation of the immune response to muscle injury increases muscle damage 
and fibrosis. (Figure taken [103]). If muscle experiences chronic trauma or if the inflammatory 
response to muscle injury is disturbed by disease or ageing, immune cells can exacerbate fiber 
damage or fibrosis. Under conditions that enhance or prolong the initial inflammatory response, 
free radicals produced by neutrophils or macrophages can induce muscle membrane lysis and 
fiber death. Neutrophil production of superoxide (O2-), hydrogen peroxide (H2O2), hypochlorous 
acid (HOCl), nitric acid (NO), and peroxynitrite (ONOO-) by NADPH oxidase, myeloperoxidase 
and inducible nitric oxide synthase can increase muscle damage. In addition, in mdx mouse 
skeletal muscle, which experiences chronic inflammation, there higher numbers of eosinophils 
that can cause further muscle fiber damage through the release of major basic protein (MBP). 
Chronic muscle damage increases the occurrence of a transitional macrophage population that can 
result in pathological increases in the number of fibro-adipogenic progenitor (FAP) cells. FAP 
cells produce elevated levels of transforming growth factor-β (TGFβ) production when stimulated 
by tumor necrosis factor (TNF) released from M1 macrophages. Chronic muscle inflammation 
leads to M2-biased phenotype macrophages in which arginase is elevated, leading to high levels 
of polyamines that can further expand fibroblast populations and proline production, ultimately 





Injury is the most common cause of death and disability in children and young 
adults, which represents a small proportion of trauma patients. A recent review of trauma 
registries in Europe found that about 10-16% of all trauma patients present with 
polytraumatic injuries [122]. For those with significant injuries to more than one region 
of the body, traffic-related accidents were the main mechanism of injury, comprising 65-
82% of all injuries across all age groups [123]. In addition, increased utilization of 
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explosive devices in recent armed conflicts have caused a dramatic increase in the rate of 
polytraumatic injuries involving injury to multiple organs or regions of the body with soft 
tissue, bone fracture, and vascular damage [124] [125].  Polytrauma comprises life-
threatening injuries that activate the innate and adaptive immune system with severe 
consequences for the host [126].  
Within minutes after polytrauma there are large increases in circulating 
complement products, including C3a and C5a, and a drop-in hemolytic activity [127]. An 
enhanced C3a/C3 ratio in plasma early after trauma is an indicator for lethal outcome 
[128] and correlates with injury severity and organ failure, including acute lung injury 
and acute renal failure [129]. One study showed that enhanced C3a levels is a marker for 
MODS (Multiple Organ Dysfunction) [130].  Anaphylatoxin C5a is a potent 
chemoattractant that enhances surface expression of intercellular adhesion molecules on 
the endothelium, thus effectively recruiting inflammatory cells to the injured site [131]. 
According to a polytrauma study, leukocytes with low C5-expression on day 1 post 
trauma, correlated with higher risks of nosocomial infections [132].   
Hemorrhagic shock is a common complication of polytrauma as well as other 
injuries. The complement role in hemorrhagic shock is complex. Complement activation 
products have been reported to change vascular tone. Which is  the degree of constriction 
experienced by a blood vessel relative to its maximally dilated state. C5a causes 
vasoconstriction of isolated pulmonary artery, which is dependent on endothelium 
integrity [133].  C5a is also involved in the pathogenesis of acute kidney injury in 
hemorrhagic shock by reducing renal blood flow by nearly 30% and the glomerular 
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filtration rate by 45% [134].  Another driver of hemorrhagic shock is 
ischemia/reperfusion injury. Several studies have shown direct complement activation 
with critical increase in C3 on the endothelium by hypoxia reperfusion conditions [135]. 
  Several mechanisms contribute to the development of MODS, including 
enhanced levels of DAMPs and PAMPs, reduce cytochrome P450 metabolism, 
macrophage activation syndrome, and cytokine driven cellular dysfunction [136]. 
Although some reduction in the frequency  of MODS after polytrauma in the last 
decades, it is still a major cause of death after severe trauma [137]. Other factors that can 
lead to MODS will be discussed. Clinically, PICS patients suffer from persistent 
inflammation, immune suppression, and protein catabolism, which result recurrent 
nosocomial infections with sepsis, MODS, and death [138]. Severe immune suppression 
of the fluid phase and cellular immune response has been termed as immune paralysis of 
the host response to sterile and infectious insults. In a clinical case, an inadequate 
response to infection with signs of depletion of complement (dropping C3 and C4 levels) 
has been linked with the development of acute kidney injury and multiple organ failure in 
a 17-year-old newborn [139]. Complements such as C5b-9 and C5a have been described 
as contributors to apoptosis, immune paralysis, and multiple organ failure [140].  
Activation of monocytes after surgery, trauma, and infection further enhances 
immune dysfunction through alterations in T lymphocyte function. Lymphopenia is 
known to occur after severe injury, and a lack of lymphocyte recovery is known to impact 
survival [141]. The conversion of effector T lymphocytes from a pro-inflammatory Th1 
phenotype to an anti-inflammatory Th2 phenotype is partially attributed to suppression 
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by regulatory T cells, which are important mediators of IL-10 and TGF-β production 
[142].  The impairment of effector helper T lymphocytes after trauma results in a 
reduction of IFN-ү production by Th1 cells [143]. IFN-ү serves a key function in 
stimulating increased antigen presentation and anti-pathogen activities innate immune 
cells [144].  Regulatory T cells express the receptor programmed death ligand 1 (PD-L1). 
A high expression of PD-1 on T lymphocytes has been linked to severity of illness after 
trauma [145]. B lymphocytes are also affected, resulting in impaired antibody production 
as well as apoptosis [146].  
 Despite early and aggressive medical treatment of patients with trauma, 
alterations in immune function following trauma can place them at risk for various 
complications. The inability to have complete resolution of SIRS or CARS can lead to 
the development of PICS. The consequences of these altered immune phenotypes can 
lead to impaired wound healing, late onset sepsis, and acute respiratory distress syndrome 
(ARDS) [147][148].  Delayed wound healing was found to be associated with higher 
serum concentrations of several inflammatory cytokines such as IL-6 and IL-8.  The 
development of MODS is frequently associated with infection and is the most common 
cause of late death in trauma patients who survive past the first 24 to 48 hours of 
resuscitation [149]. ARDS is the most common manifestation of MODS following 
trauma, with 12 to 25% of patients developing the syndrome. Trauma patients who 




SKELETAL SYSTEM INJURY 
 
The skeleton is a complex organ that provides structural support, protection of 
internal organs and its site of the hematopoietic system and a calcium reservoir. Bone is 
always in a constant state of turnover which is balanced by bone formation and 
resorption. These processes are controlled by the activity of bone resident cells including 
osteoblasts, osteocytes, and osteoclasts [150]. Fractures are the most common large-organ 
injury to humans. In about 10% of patient’s fractures do not heal properly [151].  
Fracture healing and skeletal tissue repair involves an anabolic phase 
characterized by a tissue volume increase related to the de novo recruitment and 
differentiation of stem cells that comprised skeletal and vascular tissues [151]. Adjacent 
to the fracture line, a cartilaginous callus develops. Peripheral to the region, at the edges 
of the new cartilage tissues, the periosteum swells, and primary bone formation begins 
[152][153]. Nascent blood vessels that supply the new bone are recruited and 
differentiate in the nearby muscle sheath [154]. As chondrocyte differentiation 
progresses, the cartilage extracellular matrix undertakes mineralization and the anabolic 
phase in fracture repair ends with chondrocyte apoptosis [155]. Secondary bone 
formation is initiated as cartilage is resorbed and angiogenesis continues as the nascent 
bone replaces the cartilage. As bone remodeling begins, the first mineralized matrix 
produced from primary bone formation is resorbed. As the bony callus tissue is resorbed, 
this prolonged period is known by coupled cycles of osteoblast and osteoclast activity in 
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which the callus tissues are remodeled to the bone’s cortical structure [151].  In the final 
steps of the catabolic phase, extensive vascular remodeling occurs in which the increased 
vascular area regresses and high vascular flow rate returns to pre-injury levels [156].   
The activation of PRRs induces these cells to produce inflammatory cytokines 
such as IL-1. These inflammatory cytokines have direct effects on osteoclasts and 
osteoblasts, including indirect effects on osteoclasts via osteoblast upregulation of 
RANKL, an important cytokine for osteoclastogenesis [157]. Natural killer cells and 
neutrophils have been reported to produce RANKL in inflamed synovial tissue and in 
response to LPS, but the significance compared to osteoblast, osteocyte, and T cell 
derived RANKL is still unclear [158]. Bone resident tissue macrophages found in the 
periosteum and in sites of bone remodeling in vivo suggests that these macrophages may 
contribute to tissue homeostasis. An important component of the homeostatic response to 
damage is to protect tissue integrity. Bone matrix resorption can release TGFβ, which is a 
suppressor of macrophage activation and a key mediator of tissue repair [159][160].   
 Fracture leads to suppression of the immune system with an increase in the 
number of induced regulatory (iTreg) cells that suppress adaptive immune response within 
the fracture callus [161]. Evidence for T cell involvement in fracture healing control 
stems from studies that indicate negative effects after lymphocyte depletion [162]. 
Studies of fracture healing with Rag 1-/- mice, which lack both T and B cells, revealed 
that cartilage maturation and replacement was delayed and less mineralized tissue 
accumulated, while these mice recovered mechanical function earlier than wild type mice 
[163] [164]. Another type of T cell, γδ T cells, can detect products of stressed or damaged 
32 
 
cells even in the absence of antigen presentation are also involved in fracture repair 
[165].  In other studies, mice deficient of γδ T cells have shorter fraction union times and 
earlier development of mature facture calluses than γδ-T-cell sufficient mice [166].   
 Pathophysiological events affecting the immune system can translate into 
disruption in bone homeostasis, contributing to bone loss and osteoporosis development 
in conditions associated with oestrogen deficiency and HIV infection [167][168]. T and B 
lymphocytes are implicated with bone loss associated with various conditions including 
hyperparathyroidism and rheumatoid arthritis (RA) [157].  IL-7 is regulator of peripheral 
T-cell homeostasis and has been reported as a central mediator of ovariectomy-induced 
bone loss in mice [169][170]. Elevated expression of IL-7 inflamed joints of RA patients 
have been reported in juvenile and adult RA [171][172].    
TRAUMA SUMMARY  
Central Nervous system traumas including Traumatic Brain Injury (TBI), Spinal Cord 
Injury and Hypoxia Ischemic Injury involve many similar immune cells including 
astrocytes, microglia, macrophages, and neutrophils. Some of the byproducts (cytokines 




Figure 6. Early Inflammatory response to neonatal hypoxia-ischemia in the developing 
brain. (Figure taken from [80]). Neonatal hypoxia-ischemia leads to necrotic neuronal death 
that releases danger associated pattern molecules (DAMPs). Resident immune cells (microglia 
and astrocytes) first sense these danger signals through pattern recognition receptors, such as 
TLRS and cytokine receptors, which results in inflammatory activation of microglia and 
astrocytes. Activated glia cells induce a direct neurotoxic role in promoting the neuronal 
apoptosis by releasing a large amount of pro-inflammatory cytokines, nitric oxide (NO), and 
reactive oxygen species (ROS). Synthesis and release of chemokines and matrix 
metalloproteinases (MMPs) by activated glia, together with DAMPs, increase blood-brain barrier 
(BBB) permeability, which contributes to the recruitment of peripheral inflammatory cells to 
injured brain, causing further exacerbation of neuroinflammation and consequent neuronal death.  
 
Some of the cytokines commonly expressed in all three CNS traumas include TGβ, IL-
10, and IL-1B.  Hallmark features of these CNS injuries includes the rapid recruitment of 
resident effector immune cells specifically microglia and astrocytes to the injury site as 
part of the inflammatory cascade. In addition, these cells release reactive oxygen species 
(ROS). Despite similarities, these injuries are also characterized by differences in the 
immune response. The adaptive immune response plays a vital role in spinal cord injury 
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as T and B lymphocytes remain elevated in the repair process while the exact role of the 
adaptive immune response in TBI is not clearly understood. 
 Muscle injury caused by trauma, toxins, and diseases result in an inflammatory 
response that increases the population of intramuscular leukocytes substantially within 
the first several hours of injury. Neutrophils and macrophages are some of the first 
immune cells present after injury in high numbers. Circulating macrophages release 
important cytokines such as INF-ү and TNFα that play important roles in tissue repair 
and inflammation resolution. Other immune cells, chemokines, and cytokines shown 
involved in muscle injury repair is shown in figure 7.   
 
 
Figure 7. Interactions between myeloid cells, lymphoid cells, fibro-adipogenic progenitor 
cells and myogenic precursor cells determine the course of muscle growth and regeneration. 
(Figure taken from [103]). Trauma to muscle can release molecules containing damage-
associated molecular patterns (DAMPs), such as high mobility group protein B1 (HMGB1), that 
activate and recruit immune cells to the site of trauma. This corresponds to activation of satellite 
cells to enter the cell cycle and to proliferate. The release of cytokines and chemokines, 
35 
 
specifically CC-chemokine ligand 2 (CCL2) and CXC-chemokine ligand 1 (CXCL1), from 
neutrophils, resident macrophages, and CD8+ T cells promotes further recruitment of immune 
cells to an inflammatory response driven by interferon-ү (IFN-ү) and tumor necrosis factor 
(TNF). Elevations in pro-inflammatory cytokines sustain the initial inflammatory response but act 
directly on myogenic-regulatory genes (MPCs) through epigenetic mechanisms to regulate their 
expression of myogenic regulatory genes that control MPC development. Macrophages that have 
M1 phenotype release insulin-like growth factor (IGF1), which release MPC proliferation and 
further expands the MPC population. M1 macrophage populations undergo a shift to a population 
that is biased towards a M2 pro-regenerative phenotype. Some ligands have important roles in 
promoting this phenotypic shift, including fibrinogen, amphiregulin (AREG) and interleukin-10 
(IL-10) produced by regulatory T cells (Treg), and IL-10 and IGF1 produced by macrophages. 
Phagocytosis of cellular debris also contributes to the macrophage phenotypic switch. AREG 
releases by Treg cells increases the expression of myogenic-regulatory factors that drive the further 
stages of muscle differentiation. This influence is enhanced further by the recruitment of Treg cells 
to regenerated muscle by IL-33 released by fibro-adipogenic progenitor (FAP) cells and perhaps 
by macrophages. FAP cell proliferation and differentiation into cells with phagocytic or 
fibrogenic phenotypes are influenced through the release of transforming growth factor-β (TGFβ) 
from macrophages and by IL-4 released by eosinophils. These macrophages differentiate to 
become fibroblasts then contribute to extracellular matrix production that aids muscle repair and 
the release of IGF1, which increases the growth of fully differentiated muscle.   
 
Polytrauma injuries can be caused by major traffic accidents and armed conflicts, which 
in both cases results in major regions of the body impacted. Hallmark features of 
polytrauma includes the immediate activation of the complement system with the 
presence of chemoattractant s such as C5a, immune dysregulation, and serious 




Table 2. Concentration of cytokines in plasma following trauma at 24 and 72h post-trauma. 
Plasma concentrations of analytes were determined using a Bio-plex Multiplex Immunoassay. 
Values were reported as picogram/milliliter in two experimental cohorts osteotomy and 
polytrauma at 24 and 72hr after trauma. Statically significant differences between osteonomy and 
polytrauma cohorts were indicated as follows: *p <0.05, **p<0.01; n=5/group/time point. 
Analytes that were undetectable are designated as ND [122].  
 
Based on Table 2, the concentration of some cytokines varies at different time points post 
polytrauma as seen in IL-6 and TNF-α.  
 Skeletal system injury such as fractures results in the immediate activation of the 
innate immune system with the presence of immune cells such as macrophages, DAMPS, 
and dendritic cells with aim to limit the spread of infection. The presence of cytokines 
such as TGF-β and IL-1 play vital roles in bone repair. Hallmark features of skeletal 
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injury includes the presence of specialized cells (osteoblasts and osteoclasts) in the repair 
process and RANKL regulation.  Some of the immune system cells associated in skeletal 
injury and the cytokines/chemokines released are depicted in figure 8.   
 
 
Figure 8. Effects of the immune system on bone catabolism. (Figure taken from 
[192] )  
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FUTURE DIRECTIONS AND TREATMENTS  
A. CENTRAL NERVOUS SYSTEM INJURY 
  
I. TRAUMATIC BRAIN INJURY  
Recent advances in the understanding of microglial biology during development, 
aging, neurodegeneration, and CNS repair aid researchers to better understand the role of 
microglia following traumatic brain injury. A baseline transcriptome has been established 
for microglia in healthy and aged brain using RNA Sequencing technology [174]. Similar 
studies at different stages of TBI and in different TBI models can give important 
information to define the unique transcriptional changes that occur in CNS resident 
myeloid cells during disease progression.  Identification of TBI-specific myeloid cell 
signatures according to their anatomical location and type of injury will advance the field 
and help in the development of therapies to improve clinical outcomes by modifying 
myeloid cell target genes.  A critical area of future research is the delineation of 
inflammatory processes that mobilize in response to distinct types of TBI (e.g. focal 
contusion versus diffuse concussion vs meningeal damage) [175].  This is a crucial area 
of investigation because knowing the aspects of a region-specific inflammatory response 
that mediates damage compare to repair in different types of TBI will aid in design of 
clinical trials for TBI patients with appropriate lesions and at appropriate stage of injury. 
In addition, inflammation-targeted therapies may have differential effects based on type 
(e.g. focal versus diffuse) and stage of injury (acute versus chronic); hence stratifying 
TBI data based on anatomical features, time, and severity might help to predict the 
efficacy of inflammation-based therapies that enter clinical trials [176].   
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II. Spinal Cord Injury  
Scarring and inflammatory responses to SCI include a diversity of cells and 
cellular activities that vary according on injury type, timing, and spatial distribution 
[177]. Glial and inflammatory cells affect the injury progression with significant impacts 
on overall neuronal function and SCI outcomes. Therapies targeting astrocyte activation 
and the glial scar focus on three approaches (figure 9). The first approach is the 
decomposition of inhibitory extracellular molecules produced by astrocytes with CSPGs 
(chondroitin sulfate proteoglycans) as the primary target. The second approach is to 
transplant astrocyte stem cells into the injured spinal cord formation, facilitate a tolerant 
environment through the release of growth factors and increase the effectiveness of stem 
cell therapies. The third approach is to manipulate the extracellular matrix through 
transplantation of biomaterials that provide substrates for axon growth and alter the 
inhibitory glial ECM deposition that happens after SCI [177].  Therapies targeting 
inflammation after SCI are still ongoing. To date only one therapy with 
methylprednisolone has completed phase III clinical trials with demonstrated efficacy 
[178]. The therapeutic effect of this corticosteroid is due to its anti-inflammatory 
properties including decreased macrophage activation. Recently, therapeutics targeting 
macrophages and microglia focused on two approaches. The first involves targeting 
infiltrating immune cells through macrophage deletion or antibody-based methods to 
interrupt endothelial-monocyte interactions with the goal of reducing macrophage 
activation at the injury site. The second approach is immunomodulation and promotion of 





Figure 9. Spinal Cord Injury Therapies Targeting Glial/Fibrotic Scarring and 
Inflammation. (Figure taken from [177]) Schematic of resident and infiltrating glial cells and 
associated therapies post traumatic spinal cord injury. Resident microglia and astrocytes are 
activated following injury and form a glial scar surrounding and sequestering the damaged tissue 
(top). Fibroblasts and inflammatory cells infiltrate into the damaged tissue and deposit 
extracellular matrix proteins forming a fibrous scar (middle). Activated cells exacerbate damage, 
resulting in an expanded secondary injury. Therapeutic approaches (bold) and example agents 
(hyphenated) targeting glial activation, scar formation, and inflammation after injury (bottom).   
 
 
III. Hypoxia Ischemia Injury  
Neonatal HI injury therapies are an enormous challenge. Hypothermia is the only 
validated treatment for HIE. However, this treatment has a narrow therapeutic time 
window of less than six hours and carries uncertainty with regards to optimal timing of 
initial cooling and duration of therapy [179].  In addition, hypothermia is not always 
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effective for neonates with severe injury.  IL-1β, a major cytokine associated with 
exacerbating HI has become an attractive therapeutic target.  In one study, the 
administration of recombinant IL-1 receptor antagonist (rHIL-1ra) blocking the 
inflammatory action protects against ischemic brain injury in an adult stroke model [180].  
Blocking antibodies against inflammatory mediators and/or immune cell represents a 
promising treatment strategy in neonate HI brain injury. TNF-α, a potent pro-
inflammatory cytokine induces neurotoxic effects after injury. Pretreatment with 
intravenous anti-TNF-α antibody greatly hindered the development of ischemic brain 
injury in an adult stroke rat model [181], therefore it may be effective also in HI brain 
injury in newborns. Other potential treatments include immunomodulatory therapies with 
IL-10. IL-10 is anti-inflammatory cytokine with multiple immunomodulatory actions 
against inflammation after HI. Based on adult stroke models, IL-10 treatment after 
ischemia protects against ischemic brain injury [182]. On the other hand, exact 
mechanisms underlying the immune responses to cerebral ischemic injury are most likely 
different between adults and neonates. Therefore, future research of neonatal HIE may 
involve efforts to further understand the detrimental and beneficial aspects of specific 
subsets of immune cells after neonatal hypoxia-ischemia. In addition, it is important to 
understand their causative role and molecular mechanisms in secondary neuronal injury 
and long-term neurological impairments.  




One possible treatment for muscle injury includes macrophage transplantation into 
muscle, which can improve muscle regeneration and function in chronic disease. To 
improve the engraftment of wild type MPCs in diseased muscle, dystrophic mdx mice 
were co-injected with PAX7+ MPCs and F4/80+ macrophages. This resulted in better 
engraftment of transplanted MPCs rather than injection of MPCs alone [183]. Growing 
knowledge about the immune system’s influence on muscle regeneration lead to creative 
solutions for implantable materials to repair volumetric muscle loss (VML). VML is a 
traumatic loss of muscle caused by surgery, blast injuries, or other severe trauma. Much 
work in this field focuses on the design and production of synthetic or natural scaffolding 
materials that are implanted providing a structure on which regeneration proceeds. The 
immune response to the biomaterial is a major determinant of whether the scaffold is 
compatible and support regeneration or undergoes a foreign body rejection. Skeletal 
muscle scaffolds that were successfully used for VML repair increased the populations of 
CD163+ cells and ARG1+ cells, raised IL-10 expression and reduced IFN-ү expression 
in the implanted scaffold [184].  
C. Polytrauma 
Despite improvements in trauma care, the morbidity and mortality of MODS 
remains high. Thus, new therapeutic strategies are needed. Given that the complement is 
involved in the initiation and progression of MODS, targeting complement and molecules 
contributing to complement activation represent promising future clinical approaches. In 
the context of trauma, hemorrhagic shock, and sepsis a few preclinical studies focus on 
complement-targeting strategies (table 3). Besides complement activation products, other 
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molecules including HMBG1 and mitochondrial DNA play crucial roles in aiding 
complement dysregulation after sepsis and trauma. Therefore, a rational therapeutic 
approach which includes these molecules may further boost complement activity.   Many 
complement targeting studies have been performed in mouse traumatic brain injury (TBI) 
models. Various interventions to inhibit complement activity, including MAC formation 
and C3 deposition inhibitors produced promising results. [185][186]. 
 
Table 3. Overview of observational clinical trials evaluating complement activation after 
polytrauma and sepsis [190] 
 
Based on the potential of complement inhibitors to improve micro-perfusion 
disturbances, ischemia/reperfusion injury and inflammatory responses during 
hemorrhagic shock, complement interventions have been tested in several shock models. 
In a rat model for pressure-controlled hemorrhagic shock, complement depletion of cobra 
venom factor (CVF) improved the recovery of mean arterial pressure (MAP) after 
traumatic shock [187].  In a pig model, treatment with a C1-inhibitor improved the 
functional performance and reduced C3 deposition on a multi-organ level including liver 
and lungs [188].  Similarly, intestinal injury caused by hypovolemic shock in mice was 
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ameliorated with the application of a small peptide C5aR1 antagonist and C5 deficient 
littermates [189].   
 Three interventional trials have been initiated to date (Table 4). One study 
addressed the inhibition of upstream complement component (C1) by targeting C1 
esterase.  Another clinical trial was performed to study complement inhibition in newly 
developing septic organ dysfunction with the application of a monoclonal antibody 
against C5a.  C5 inhibition has dual effects on patients such as improved sepsis and 
impaired blood brain barrier, on the other hand neuroprotective effects by C5a might be 
compromised. [189].  Future studies and translational efforts will be needed for targeting 
complement pathways in trauma settings, hemorrhagic shock, and sepsis with the goal to 
offer therapies and better outcome.   
 
Table 4. Overview of complement therapeutics for clinical trials [190]. 
D. Skeletal System Injury  
Several strategies have been developed to enhance fracture healing through either 
biophysical or biological means. For biophysical enhancement, research has been 
conducted on the use of electromagnetic fields and low-intensity pulsed ultrasonography. 
In biological enhancement, strategies can be subdivided into local and systemic. Local 
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strategies for repair and bone regeneration include the use of osteogenic materials such as 
autologous bone marrow and growth factors. Bone morphogenetic proteins (BMPs) are 
probably the most extensively investigated candidates for the enhancement of skeletal 
repair, especially recombinant BMP-2, and BMP-7. The FDA granted premarket 
approval for recombinant human BMP-2 and the treatment is now available in several 
countries for the treatment of fresh, open tibial fractures [191].  Future directions of 
potential treatments include new systemic biological enhancements such as the use of 
PHT or humanized monoclonal anti-sclerostin. Ideally, a patient with a bone fracture 
could be treated with an injection or pill that would enhance or augment skeletal healing 
instead of surgical treatments.   
CONCLUSION  
Trauma will continue to be a global problem as incidences globally continue to 
rise and place an economic burden on medical systems. Different types of trauma such as 
traumatic brain injury and polytrauma involve host immune responses to restore 
homeostasis. Host immune system responses in many cases can result in unintended 
complications including sepsis, multiorgan failure, and hemorrhagic shock. These 
complications all increase the risk of death . Treatment options are hard to develop in 
these complex situations when subsets of different immune cells and inflammatory 
mediators have a multitude and often opposing effects depending on injury and disease 
stage. Despite these limitations, with early intervention and treatment management more 
trauma patients today recover. Future research into treatments to various injuries look 
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